15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 14 firms covering Pfizer Inc, 5 rate it Buy or better, 8 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets span $25.00 to $35.00, a moderate spread. The average target of $28.46 sits 2% above the current $27.79. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.71 next quarter toward $2.90 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 ratings
Moderate Buy
Strong Buy00%
Buy536%
Hold857%
Sell17%
Strong Sell00%
Based on 14 analysts giving stock ratings to Pfizer Inc.
As of Sep, 5 of 14 firms rate PFE a Buy (8 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
PFE EPS & revenue forecast
EPS · NEXT QUARTER
$0.71
Range $0.60 – $0.81 · 18 analysts · +7% YoY
Next period, 18 analysts expect Pfizer Inc to earn $0.71 a share (range $0.60 – $0.81), versus $0.66 a year earlier. Full-year consensus is $2.98, growing to $2.90 the year after.
REVENUE · NEXT QUARTER
$16.9B
Range $16.1B – $18.1B · 18 analysts · -4% YoY
Revenue is expected to reach $16.9B (range $16.1B – $18.1B), -3.9% year-over-year. Full-year consensus is $62.2B, rising to $59.8B next year.
Top analysts covering Pfizer Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PFE.
#1
Jason Gerberry
B of A Securities · Rank #125
Hold
$27.00-2.8% to target
Overall win rate
46%
+ Follow
#2
Vamil Divan
Guggenheim
Buy
$31.00+11.6% to target
Coverage
—
+ Follow
#3
Terence Flynn
Morgan Stanley
Hold
$28.00+0.8% to target
Coverage
—
+ Follow
#4
Carter Gould
Cantor Fitzgerald
Hold
$27.00-2.8% to target
Coverage
—
+ Follow
#5
Geoff Meacham
Citigroup
Hold
No targeton PFE
Coverage
—
+ Follow
PFE stock forecast FAQ
What is PFE's average 12-month price target?+
The 13 analysts with a live target average $28.46 for Pfizer Inc over the next 12 months, ranging from a $35.00 high to a $25.00 low.
Is PFE stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 14 analyst ratings, 5 are Buy or Strong Buy, 8 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for PFE?+
The Street-high target is $35.00 (Argus Research), and the Street-low is $25.00 (RBC Capital). The average of all 13 active targets is $28.46.
How many Wall Street analysts cover PFE?+
14 analysts have an active rating on Pfizer Inc, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering PFE?+
Among analysts who currently cover PFE, Jason Gerberry of B of A Securities has the strongest overall Quantellect track record (Rank #125). Their current call is Hold with a $27.00 target.
What is Pfizer Inc's projected EPS for next quarter?+
The consensus estimate is $0.71 per share (range $0.60 – $0.81) across 18 analysts. Full-year EPS is projected at $2.98, rising to $2.90 the following year.
How much revenue is Pfizer Inc expected to report next quarter?+
Consensus revenue is $16.9B (range $16.1B – $18.1B). Full-year revenue is projected at $62.2B, growing to $59.8B next year.
Have analysts been upgrading or downgrading PFE lately?+
As of Sep, 5 of 14 firms rate PFE a Buy (8 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PFE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
